Nevro Corp (N:NVRO)

Business Focus: Medical Equipment, Supplies & Distribution

Apr 17, 2024 08:30 am ET
Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024
REDWOOD CITY, Calif., April 17, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the first quarter of 2024 after the market closes on Tuesday, May 7, 2024. The company will also host a conference call beginning at 1:30 p.m. PDT (4:30 p.m. EDT) to discuss its financial results.
Feb 21, 2024 03:06 pm ET
Nevro Enters Into Cooperation Agreement With Engaged Capital
Appoints Kirt P. Karros to Board of Directors
Feb 21, 2024 03:05 pm ET
Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
Provides Full-Year and First-Quarter 2024 Guidance
Feb 01, 2024 03:30 pm ET
Nevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic Neuropathy
Experts in diabetes, pain and health services from the Worldwide Initiative for Diabetes Education recommend spinal cord stimulation when symptoms aren't responsive to first- or second-line therapies
Jan 29, 2024 03:30 pm ET
Nevro to Report Fourth-Quarter and Full-Year 2023 Financial Results and Host Conference Call on February 21, 2024
REDWOOD CITY, Calif., Jan. 29, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will release its financial results for the fourth quarter and full year ended December 31, 2023 after the market closes on Wednesday, February 21, 2024.
Jan 22, 2024 03:00 am ET
Top 4 Spinal Injury Stocks for 2024 (NRX.V, NVRO, SYK, BSX)
Investors eyeing dynamic opportunities in healthcare should take note of the burgeoning growth anticipated in the spinal cord injury market. Projections for robust advancements, driven by enhanced diagnosis and increased global healthcare spending, signal a lucrative trajectory from 2023 to 2032, with a significantly positive CAGR, according to Delveinsights.
Jan 18, 2024 03:15 pm ET
Nevro Announces Positive Coverage Update from Carelon Healthcare for the Treatment of Painful Diabetic Neuropathy
Spinal Cord Stimulation Coverage Policy to Include 43 Million Additional Covered Lives
Jan 17, 2024 03:15 pm ET
Nevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual Meeting
Presentations review clinical results of 10 kHz Therapy™ for the treatment of chronic backand leg pain, non-surgical back pain (NSBP), and painful diabetic neuropathy (PDN)
Jan 09, 2024 07:30 am ET
Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results
Fourth-Quarter 2023 Worldwide Revenue Exceeds Company's Expectations
Jan 04, 2024 03:15 pm ET
Nevro to Present at 42nd Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 4, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that members of its management team will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024. The company's formal presentation will begin at 8:15 am PST (11:15 am EST).
Nov 30, 2023 04:19 pm ET
Nevro Announces Acquisition of Vyrsa™ Technologies
Refinances with $200M Structured Debt Maturing in 2029
Nov 20, 2023 06:00 am ET
Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain
Data Published in Journal of Neurosurgery: Spine Highlight Lasting Pain Relief, Enhanced Function, Quality of Life, and Reduced Opioid Dependency with High-Frequency SCS Therapy
Nov 01, 2023 04:01 pm ET
Nevro Reports Third Quarter 2023 Financial Results, Provides Fourth Quarter Guidance and Updates Full-Year 2023 Guidance
REDWOOD CITY, Calif., Nov. 1, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its third quarter 2023 financial results. The Company also provided fourth quarter guidance and updated its full-year 2023 guidance.
Oct 04, 2023 07:00 am ET
Nevro to Report Third Quarter 2023 Financial Results
Company to Host Conference Call on Wednesday, November 1, 2023 at 1:30 pm PT / 4:30 pm ET
Sep 18, 2023 07:00 am ET
New Data Demonstrate the Health Economic Benefits of Nevro's High-Frequency Spinal Cord Stimulation Therapy
Publications Show Reductions in Hospital Resource Utilization Associated with 10 kHz Therapy Spinal Cord Stimulation for the Treatment of Painful Diabetic Neuropathy and Nonsurgical Refractory Back Pain
Aug 01, 2023 04:03 pm ET
Nevro Reports Second Quarter 2023 Financial Results, Provides Third Quarter Guidance and Updates Full-Year 2023 Guidance
Company Takes Proactive Steps to Improve Commercial Execution and Maximize Growth Opportunities
Jul 13, 2023 07:00 am ET
Nevro Announces Presentations at American Society of Pain & Neuroscience Fifth Annual Conference
Abstract Presentations Highlight Durable Pain Relief and Improved Quality of Life for Patients Receiving 10 kHz Spinal Cord Stimulation Therapy for Painful Diabetic Neuropathy and Non-Surgical Back Pain 
Jul 12, 2023 07:00 am ET
Nevro to Present at the Canaccord Genuity 43rd Annual Growth Conference
Wednesday, August 9, 2023 at 8:30 am Eastern Time
Jun 27, 2023 07:00 am ET
Nevro to Report Second Quarter 2023 Financial Results
Company to Host Conference Call on Tuesday, August 1, 2023 at 1:30 pm PT / 4:30 pm ET
Jun 23, 2023 07:00 am ET
Nevro Announces Painful Diabetic Neuropathy Clinical Data Presentations at the American Diabetes Association 83rd Scientific Sessions
Presentation to Discuss Correlation Between Use of High-Frequency (10 kHz) Spinal Cord Stimulation and Reductions in HbA1c and Body Weight
Jun 05, 2023 04:05 pm ET
Nevro Names New Chief Commercial Officer
Organizational Change Designed to Drive Strong Growth and Advance Global Commercial Focus
May 22, 2023 07:00 am ET
Nevro to Present at Jefferies Healthcare Conference
Thursday, June 8, 2023 at 10:30 am Eastern Time
Apr 27, 2023 04:05 pm ET
Nevro Corp. Announces New Employment Inducement Grant under Section 303A.08 of the NYSE Listed Company Manual
REDWOOD CITY, Calif., April 27, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced on April 24, 2023, the Board of Director of Nevro granted restricted stock unit awards covering an aggregate of 135,623 shares of its common stock (the RSU Award) and performance unit awards covering 135,623 shares of its common stock (the PSU Award and together, the Awards) to Kevin Thornal, who joined Nevro as its Chief Executive Officer & President, in connection with
Apr 26, 2023 04:05 pm ET
Nevro Reports First Quarter 2023 Financial Results, Provides Second Quarter Guidance and Reiterates Full-Year 2023 Guidance
REDWOOD CITY, Calif., April 26, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its first quarter 2023 financial results.  The company also provided second quarter guidance and reiterated its full-year 2023 guidance.
Apr 24, 2023 05:03 pm ET
Nevro Announces Enrollment of First Patient in PDN Sensory Study
First Randomized Controlled Trial Specifically Powered to Assess Restoration of Neurological Function in Patients with Intractable Painful Diabetic Neuropathy
Apr 24, 2023 07:00 am ET
Nevro Announces Participation in Upcoming Investor Conferences
REDWOOD CITY, Calif., April 24, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced today that it is participating in the following investor conferences:
Apr 19, 2023 05:05 pm ET
Nevro Names Kevin Thornal as New Chief Executive Officer and President
D. Keith Grossman to be Appointed as Executive Chairman
Mar 29, 2023 07:00 am ET
Nevro to Report First Quarter 2023 Financial Results
Company to Host Conference Call on Wednesday, April 26, 2023 at 1:30 pm PT / 4:30 pm ET
Feb 23, 2023 03:05 pm ET
Feb 16, 2023 03:05 pm ET
Nevro Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides First Quarter and Complete Full-Year 2023 Guidance
REDWOOD CITY, Calif., Feb. 16, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced its fourth quarter and full-year 2022 financial results.  The company also provided first quarter and complete full-year 2023 guidance.
Feb 01, 2023 06:00 am ET
Jan 31, 2023 03:05 pm ET
Nevro Named to 2023 Bloomberg Gender-Equality Index for Second Consecutive Year
Leading Indicator Aimed at Increasing Transparency Surrounding Gender-Related Practices and Policies
Jan 19, 2023 06:00 am ET
Nevro to Report Fourth Quarter and Full-Year 2022 Financial Results
Company to Host Conference Call on Thursday, February 16, 2023 at 1:30 pm PT / 4:30 pm ET
Jan 12, 2023 06:00 am ET
Nevro to Highlight New Clinical Evidence at the 2023 North American Neuromodulation Society (NANS) 26th Annual Meeting
REDWOOD CITY, Calif., Jan. 12, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced a series of data presentations supporting the use of the company's HFX™ 10 kHz Therapy for patients with chronic pain.  Results will be presented at the 2023 North American Neuromodulation Society (NANS) Annual Meeting held from January 12-15, 2023.
Jan 09, 2023 05:00 am ET
Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2022 Revenue and Provides Full-Year 2023 Revenue Guidance
Company Announces 2023 Retirement Plans of D. Keith Grossman from Positions of CEO and President; Will Remain as Chairman of the Board
Dec 19, 2022 03:05 pm ET
Nevro to Present at 41st Annual J.P. Morgan Healthcare Conference
Monday, January 9, 2023 at 3:45 pm Pacific Time / 6:45 pm Eastern Time
Nov 02, 2022 04:05 pm ET
Nevro Reports Third Quarter 2022 Financial Results, Narrows Full-Year 2022 Guidance and Raises Revenue Contribution from Painful Diabetic Neuropathy
REDWOOD CITY, Calif., Nov. 2, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its financial results for the third quarter ended September 30, 2022, narrowed its full-year 2022 guidance and raised its full-year revenue contribution from painful diabetic neuropathy (PDN).
Oct 12, 2022 06:13 pm ET
Nevro Announces FDA Approval of HFX iQ™ Spinal Cord Stimulation System to Personalize the Treatment of Chronic Pain
Next Generation Senza® HFX iQ™ is the First and Only SCS System that Uses Artificial Intelligence to Optimize and Maintain Pain Relief Using Each Patient's Response
Oct 10, 2022 07:00 am ET
Nevro Comments on UnitedHealthcare Medical Coverage Policy Update
REDWOOD CITY, Calif., Oct. 10, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that on October 1, 2022, UnitedHealthcare ("United") released an update to its medical coverage policy (number 2022T0567V) and added language to indicate spinal cord stimulation (SCS) devices are not covered for treating chronic intractable back pain without prior spine surgery (NSBP). This policy becomes effective on December 1, 2022.  All other elements of their SCS coverage
Oct 05, 2022 07:00 am ET
Nevro to Report Third Quarter 2022 Financial Results
Company to Host Conference Call on Wednesday, November 2, 2022 at 1:30 pm PT / 4:30 pm ET
Oct 04, 2022 04:05 pm ET
Nevro Announces FDA Approval of Costa Rica Manufacturing Operations
REDWOOD CITY, Calif., Oct. 4, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced today that the U.S. Food and Drug Administration (FDA) has approved its manufacturing operations in Costa Rica for the production of its proprietary spinal cord stimulation systems for the treatment of chronic pain, including its HFX product platform.  
Oct 03, 2022 07:00 am ET
Nevro Announces American Association of Clinical Endocrinology Clinical Practice Guideline Has Been Updated to Include High-Frequency 10 kHz Spinal Cord Stimulation to Treat Painful Diabetic Neuropath
REDWOOD CITY, Calif., Oct. 3, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that Nevro's HFX 10 kHz Therapy is the only form of spinal cord stimulation (SCS) therapy to be referenced by the American Association of Clinical Endocrinology (AACE) in its 2022 Diabetes Clinical Practice Guideline to treat painful diabetic neuropathy (PDN).
Sep 01, 2022 07:00 am ET
Nevro Announces Multiple Positive Coverage Updates for the Treatment of Painful Diabetic Neuropathy
Aetna Updates Spinal Cord Stimulation Coverage Policy to Include Painful Diabetic Neuropathy Effective Immediately
Aug 09, 2022 07:00 am ET
Nevro Announces Participation In Upcoming Investor Conferences
REDWOOD CITY, Calif., Aug. 9, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced today that it is participating in the following investor conferences:
Aug 03, 2022 04:05 pm ET
Nevro Reports Second Quarter 2022 Financial Results, Provides Third Quarter 2022 Guidance and Updates Full-Year 2022 Guidance
REDWOOD CITY, Calif., Aug. 3, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its financial results for the second quarter ended June 30, 2022, provided guidance for the third quarter of 2022 and updated its full-year 2022 guidance.
Aug 01, 2022 07:00 am ET
Nevro and Boston Scientific Announce the Settlement of Their Ongoing Intellectual Property Litigations
Parties Reach an Agreement that Concludes Outstanding Intellectual Property Disputes
Jul 21, 2022 07:00 am ET
Nevro to Present at the Canaccord Genuity 42nd Annual Growth Conference
Wednesday, August 10, 2022 at 2:30 pm Eastern Time
Jun 07, 2022 04:05 pm ET
Clinical Data Presented at American Diabetes Association 82nd Scientific Sessions Reinforce Significant and Durable Benefits of Nevro's HFX 10 kHz Therapy
SENZA-PDN Randomized Controlled Trial Results From Original 10 kHz Arm Demonstrate Significant and Sustained Outcomes with 10 kHz Therapy at 24-Months Follow-Up
May 31, 2022 04:05 pm ET
Nevro Announces SENZA-PDN Clinical Data Presentations at the American Diabetes Association 82nd Scientific Sessions
Poster Presentation to Include 24-Month Follow-Up Results from Original 10 kHz Arm of SENZA-PDN Randomized Controlled Trial
May 04, 2022 04:05 pm ET
Nevro Reports First Quarter 2022 Financial Results, Provides Second Quarter 2022 Guidance and Reiterates Full-Year 2022 Guidance
REDWOOD CITY, Calif., May 4, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its financial results for the first quarter ended March 31, 2022, provided guidance for the second quarter of 2022 and reiterated its full-year 2022 revenue guidance.
Apr 06, 2022 07:00 am ET
Nevro to Report First Quarter 2022 Financial Results
Company to Host Conference Call on Wednesday, May 4, 2022 at 1:30 pm PT / 4:30 pm ET
Mar 07, 2022 03:05 pm ET
Nevro Announces Positive Medicare Coverage Update from Noridian for the Treatment of Painful Diabetic Neuropathy
REDWOOD CITY, Calif., March 7, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that Noridian, the Medicare Administrative Contractor (MAC) that oversees the majority of the western United States, released an update to their Local Coverage Billing and Coding article (A57791 and A57792) for spinal cord stimulators for chronic pain to include two new ICD-10 codes that cover Painful Diabetic Neuropathy (PDN).  This change was posted on March 4, 2022 and is r
Feb 23, 2022 03:05 pm ET
Nevro Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides First Quarter and Full-Year 2022 Guidance
REDWOOD CITY, Calif., Feb. 23, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its financial results for the fourth quarter and full-year ended December 31, 2021 and provided guidance for the first quarter and full-year of 2022.
Feb 18, 2022 06:00 am ET
Nevro to Participate in Wells Fargo 2022 MedTech R&D Spotlight Call Series
REDWOOD CITY, Calif., Feb. 18, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, Rod MacLeod, Chief Financial Officer, and Dr. David Caraway, Chief Medical Officer, will participate in the Wells Fargo 2022 MedTech R&D Spotlight Call Series on Friday, March 4, 2022 at 10:00 am Eastern Time.
Feb 11, 2022 07:30 am ET
Nevro Announces Publication of 12-Month Data from SENZA-NSRBP Randomized Controlled Trial in Journal of Neurosurgery: Spine
REDWOOD CITY, Calif., Feb. 11, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced 12-month data from the SENZA-NSRBP randomized controlled trial (RCT) was published online in Journal of Neurosurgery: Spine.1 These data show that high-frequency 10 kHz spinal cord stimulation (SCS) therapy results in profound improvement in non-surgical refractory back pain (NSRBP) patients compared to Conventional Medical Management (CMM).    
Jan 31, 2022 06:00 am ET
Nevro to Present at Citi's 2022 Virtual Healthcare Conference
REDWOOD CITY, Calif., Jan. 31, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present at Citi's 2022 Virtual Healthcare Conference on Thursday, February 24, 2022 at 12:30 pm Eastern Time.
Jan 26, 2022 03:05 pm ET
Nevro Named to 2022 Bloomberg Gender-Equality Index
REDWOOD CITY, Calif., Jan. 26, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has been named to the 2022 Bloomberg Gender-Equality Index (GEI).  The GEI is a modified market capitalization-weighted index that aims to track the performance of public companies committed to transparency in gender-data reporting.  This index measures gender equality across five pillars: female leadership & talent pipeline, equal pay & gender pay parity, incl
Jan 19, 2022 06:00 am ET
Nevro Announces FDA Approval for Expanded Labeling for its 10 kHz High Frequency Spinal Cord Stimulation System for Treatment of Non-Surgical Refractory Back Pain (NSRBP)
REDWOOD CITY, Calif., Jan. 19, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced receipt of FDA approval for expanded labeling for its Senza® Spinal Cord Stimulation (SCS) System for the treatment of Non-Surgical Refractory Back Pain (NSRBP).  This approval is specific to Nevro's proprietary 10 kHz Therapy and differentiates Nevro's Senza System as the only SCS system with specific labeling to treat NSRBP patients.
Jan 18, 2022 06:00 am ET
Clinical Data Presented at 2022 North American Neuromodulation Society (NANS) Annual Meeting Reinforce Significant and Durable Benefits of Nevro's 10 kHz Therapy
REDWOOD CITY, Calif., Jan. 18, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced  the results from data presentations at the 2022 North American Neuromodulation Society (NANS) Annual Meeting supporting the use of 10 kHz spinal cord stimulation (SCS) therapy for patients with chronic pain, including results from the SENZA Painful Diabetic Neuropathy (PDN) and SENZA Non-Surgical Refractory Back Pain (NSRBP) randomized clinical trials (RCT).  Results were pre
Jan 10, 2022 05:00 am ET
Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2021 Revenue
REDWOOD CITY, Calif., Jan. 10, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced its preliminary, unaudited fourth quarter and full-year 2021 revenue results and expects to exceed the high end of its previously provided fourth quarter 2021 non-GAAP adjusted EBITDA guidance.    
Jan 04, 2022 06:00 am ET
Nevro Announces UnitedHealthcare Coverage for High-Frequency 10 kHz Therapy for the Treatment of Painful Diabetic Neuropathy
REDWOOD CITY, Calif., Jan. 4, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that UnitedHealthcare, the largest private health insurance company in the United States, will provide coverage for the company's high-frequency 10 kHz Therapy for the treatment of PDN (Painful Diabetic Neuropathy) for dates of service on or after March 1, 2022. UnitedHealthcare is one of the businesses of UnitedHealth Group, a diversified health care company that provides cove
Dec 21, 2021 03:05 pm ET
Nevro Announces Settlement of IP Litigation with Nalu Medical
REDWOOD CITY, Calif., Dec. 21, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today announced the settlement of its patent lawsuit with Nalu Medical. 
Dec 20, 2021 06:00 am ET
CORRECTING AND REPLACING -- Nevro to Present at 40th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Dec. 20, 2021 /PRNewswire/ -- In a release issued under the same headline on December 10, 2021 by Nevro Corp. (NYSE: NVRO), please note that the presentation time has been updated. The correct presentation time is 1:30 pm Pacific Time / 4:30 pm Eastern Time.  All other information remains the same. 
Dec 13, 2021 06:00 am ET
Nevro Announces Three Podium Presentations from SENZA-PDN and SENZA-NSRBP Clinical Trials Have Been Accepted for Late-Breaking Abstract Sessions at NANS 2022 Annual Meeting
REDWOOD CITY, Calif., Dec. 13, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that three abstracts for Painful Diabetic Neuropathy (PDN) and Non-Surgical Refractory Back Pain (NSRBP) were accepted for podium presentation at the 2022 North American Neuromodulation Society Annual Meeting (NANS 2022) and will be presented during the late-breaking plenary sessions on January 15, 2022.  Following these data presentations, Nevro plans to issue a press release su
Dec 10, 2021 06:00 am ET
Nevro to Present at 40th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Dec. 10, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 7:30 am Pacific Time / 10:30 am Eastern Time at the Westin St. Francis Hotel in San Francisco, CA.
Nov 30, 2021 06:00 am ET
Nevro Announces Two Health Economic Poster Presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2021 Meeting
REDWOOD CITY, Calif., Nov. 30, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced two poster presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2021 virtual meeting.  ISPOR is a leading professional society for health economics and outcomes research.   
Nov 29, 2021 10:05 am ET
Nevro Announces Three Important Clinical Data Publications for Treating Painful Diabetic Neuropathy with 10 kHz Therapy
REDWOOD CITY, Calif., Nov. 29, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced three important clinical data publications for treating Painful Diabetic Neuropathy (PDN) with 10 kHz Therapy, including 12-month data from the landmark SENZA-PDN Randomized Controlled Trial (RCT) published online in Diabetes Care, as well as real-world evidence and a comparative literature review of high vs. low frequency SCS evidence, both published in the Journal of Diabetes S
Nov 08, 2021 03:05 pm ET
Nevro Reports Third Quarter 2021 Financial Results and Provides Fourth Quarter Guidance
REDWOOD CITY, Calif., Nov. 8, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today reported its financial results for the third quarter ended September 30, 2021 and provided fourth quarter of 2021 guidance.
Nov 01, 2021 06:31 pm ET
Nevro Announces Update in Patent Litigation with Boston Scientific
REDWOOD CITY, Calif., Nov. 1, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today announced that a Delaware jury found that Nevro infringed two Boston Scientific patents (7,891,085 and 8,019,439) directed to ways of manufacturing spinal cord stimulation (SCS) leads, which Nevro obtains from a third-party supplier.  Two other Boston Scientific lead patents (8,646,172 and 8,650,747) were not infringed.  The jury awarded Boston Scientific $20 million.  This decision has no comm
Oct 25, 2021 06:00 am ET
Nevro to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
REDWOOD CITY, Calif., Oct. 25, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference.  Mr. Grossman's presentation will be available beginning Monday, November 22, 2021 at 10:00 am Eastern Time / 7:00 am Pacific Time.
Oct 11, 2021 06:00 am ET
Nevro to Report Third Quarter 2021 Financial Results
REDWOOD CITY, Calif., Oct. 11, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the company will report its financial results for the third quarter ended September 30, 2021 after the market closes on November 8, 2021.
Aug 31, 2021 04:05 pm ET
Nevro Announces Director Appointment
REDWOOD CITY, Calif., Aug. 31, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today announced that Sri Kosaraju has been appointed as a member of the Board of Directors (the "Board"), effective August 31, 2021.
Aug 26, 2021 06:00 am ET
Nevro to Present at Baird 2021 Global Healthcare Conference
REDWOOD CITY, Calif., Aug. 26, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present at the Baird 2021 Global Healthcare Conference on Wednesday, September 15, 2021 at 10:50 am Eastern Time / 7:50 am Pacific Time.
Aug 25, 2021 09:00 am ET
Supermoon Capital Launches with World's First Fund Focused on Sleep
SAN FRANCISCO, Aug. 25, 2021 /PRNewswire/ -- Supermoon Capital (www.supermooncapital.com), formerly SleepScore Ventures, launched today with its first venture fund of $36 million to invest in early-stage startups across all geographies working on science-backed innovations aimed to improve sleep. With the world's first fund investing in sleep, Supermoon Capital aims to address the rapidly emerging category of the Night Market™, the firm's name for the budding $488 billion sleep economy.
Aug 25, 2021 06:00 am ET
Nevro to Present at Morgan Stanley 19th Annual Global Healthcare Conference
REDWOOD CITY, Calif., Aug. 25, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present at the Morgan Stanley 19th Annual Global Healthcare Conference on Monday, September 13, 2021 at 11:45 am Eastern Time / 8:45 am Pacific Time.
Aug 23, 2021 06:00 am ET
Nevro to Present at Wells Fargo Virtual Healthcare Conference
REDWOOD CITY, Calif., Aug. 23, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present at the Wells Fargo Virtual Healthcare Conference on Friday, September 10, 2021 at 8:00 am Eastern Time / 5:00 am Pacific Time.
Aug 04, 2021 04:05 pm ET
Nevro Reports Second Quarter 2021 Financial Results and Provides Third Quarter of 2021 Guidance
REDWOOD CITY, Calif., Aug. 4, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today reported its financial results for the second quarter ended June 30, 2021 and provided third quarter of 2021 guidance.
Jul 19, 2021 07:00 am ET
Nevro Announces FDA Approval of its 10 kHz High Frequency Spinal Cord Stimulation Therapy for Treatment of Chronic Pain Associated with Painful Diabetic Neuropathy (PDN)
REDWOOD CITY, Calif., July 19, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced receipt of FDA approval of its Senza® System for the treatment of chronic pain associated with Painful Diabetic Neuropathy (PDN).  This approval is specific to Nevro's unique 10 kHz stimulation, and Nevro now has the only spinal cord stimulation system approved by the FDA with a specific indication to treat PDN.  The company will immediately initiate commercial launch activities
Jul 07, 2021 07:00 am ET
Nevro to Report Second Quarter 2021 Financial Results
REDWOOD CITY, Calif., July 7, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the company will report its financial results for the second quarter ended June 30, 2021 after the market closes on August 4, 2021.
Jun 22, 2021 06:00 am ET
Nevro Announces SENZA-NSRBP Clinical Data Presentation at the American Society of Interventional Pain Physicians 23rd Annual Meeting
REDWOOD CITY, Calif., June 22, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that data from the SENZA Non-Surgical Refractory Back Pain (NSRBP) Randomized Controlled Trial (RCT) will be presented at the American Society of Interventional Pain Physicians (ASIPP) 23rd annual meeting to be held in person from June 24-26, 2021 at the Hilton New Orleans Riverside in New Orleans, Louisiana.  Nevro will also showcase the company's HFX™ platform of spinal cord st
Jun 22, 2021 06:00 am ET
Nevro Announces SENZA-PDN Clinical Data Presentation at the American Diabetes Association 81st Scientific Sessions
REDWOOD CITY, Calif., June 22, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that data from the SENZA Painful Diabetic Neuropathy (PDN) Randomized Controlled Trial (RCT) will be presented at the American Diabetes Association (ADA) 81st Scientific Sessions virtual meeting, June 25-29, 2021.  Nevro will also showcase the company's HFX™ platform of spinal cord stimulation (SCS) solutions in a virtual booth and will host an investor briefing. 
Jun 14, 2021 07:00 am ET
Nevro to Host Virtual Analyst & Investor Briefing
REDWOOD CITY, Calif., June 14, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced it will host an analyst & investor briefing from the American Diabetes Association 81st Scientific Sessions on Friday, June 25, 2021, beginning at 3:30 pm PT / 6:30 pm ET.  Nevro Chairman, CEO and President D. Keith Grossman will host the event, which will include a clinical data update for the company's SENZA-PDN and SENZA-NSRBP clinical studies and a question & answer s
Feb 24, 2021 03:05 pm ET
Nevro Reports Fourth Quarter and Full Year 2020 Financial Results
REDWOOD CITY, Calif., Feb. 24, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today reported its financial results for the fourth quarter and full year ended December 31, 2020 and provided 2021 guidance.
Feb 01, 2021 06:00 am ET
Nevro to Present at 10th Annual SVB Leerink Global Healthcare Conference
REDWOOD CITY, Calif., Feb. 1, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present at the 10th Annual SVB Leerink Global Healthcare Conference on Friday, February 26, 2021 at 10:40 am Eastern Time / 7:40 am Pacific Time.
Feb 01, 2021 06:00 am ET
Nevro to Present at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference
REDWOOD CITY, Calif., Feb. 1, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference on Thursday, February 25, 2021 at 1:30 pm Eastern Time / 10:30 am Pacific Time.
Jan 27, 2021 06:00 am ET
Nevro to Report Fourth Quarter and Full-Year 2020 Financial Results
REDWOOD CITY, Calif., Jan. 27, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the company will report its financial results for the fourth quarter and full-year ended December 31, 2020 after the market closes on February 24, 2021.
Jan 19, 2021 06:00 am ET
Clinical Data Presented at 2021 North American Neuromodulation Society (NANS) Virtual Meeting Reinforce Significant Benefits of Nevro's HF10® Therapy
REDWOOD CITY, Calif., Jan. 19, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced  the results from data presentations at NANS supporting the use of HF10® therapy for patients with chronic pain, including results from the Painful Diabetic Neuropathy (PDN) and Non-Surgical Refractory Back Pain (NSRBP) randomized clinical trials (RCT).  Results were presented at the 2021 North American Neuromodulation Society (NANS) Virtual Meeting held from January 14-16, 2021.
Jan 14, 2021 06:00 am ET
Nevro to Highlight New Clinical Evidence at the 2021 North American Neuromodulation Society (NANS) Virtual Meeting
REDWOOD CITY, Calif., Jan. 14, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced a series of data presentations supporting the use of the company's HF10® therapy for patients with chronic pain.  Results will be presented at the 2021 North American Neuromodulation Society (NANS) Virtual Meeting held from January 14-16, 2021.
Jan 11, 2021 06:00 am ET
Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2020 Revenue
REDWOOD CITY, Calif., Jan. 11, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced its preliminary, unaudited revenue for the fourth quarter and full-year ended December 31, 2020.
Dec 28, 2020 03:08 pm ET
Nevro Announces FDA Submission for HF10® Therapy in Patients with Painful Diabetic Neuropathy
REDWOOD CITY, Calif., Dec. 28, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the company has submitted a pre-market approval supplement to the U.S. Food and Drug Administration (FDA) to seek approval of its Senza® System for the treatment of chronic pain associated with Painful Diabetic Neuropathy (PDN).
Dec 22, 2020 03:05 pm ET
Nevro to Host Virtual Investor Briefing at 2021 North American Neuromodulation Society (NANS) Virtual Conference
REDWOOD CITY, Calif., Dec. 22, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced it will host and webcast a virtual investor briefing at the 2021 North American Neuromodulation Society (NANS) Virtual Conference on Friday, January 15, 2021, beginning at 4:00 pm PST / 6:00 pm CST.  Nevro Chairman, CEO and President D. Keith Grossman will host the event and will provide a business update and answer questions from investors about the Company's latest developments
Dec 15, 2020 03:05 pm ET
Nevro to Present at 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021
REDWOOD CITY, Calif., Dec. 15, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021, at 4:30 pm Eastern Time / 1:30 pm Pacific Time.
Dec 14, 2020 05:54 pm ET
Boston Scientific Announces Stipulation Of Dismissal Of Nevro Corporation's Patent Infringement Case In California
MARLBOROUGH, Mass., Dec. 14, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that a stipulation of dismissal has been filed in the Nevro Corporation (NYSE: NVRO) patent infringement case against Boston Scientific in the United States District Court for the Northern District of California. Nevro sought preliminary and permanent injunctive relief against further infringement as well as damages and attorney's fees. The case has now ended, with Nevro receiving none of its requested relief. There was no ruling which would impose any restrictions on any current or fu
Dec 14, 2020 03:30 pm ET
Nevro Announces Agreement to Conclude Its Patent Lawsuit in the Northern District of California Against Boston Scientific
REDWOOD CITY, Calif., Dec. 14, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that, in its patent litigation against Boston Scientific, the parties agreed to the dismissal of the patent case filed by Nevro in the Northern District of California relating to high frequency paresthesia-free SCS therapy.  The official dismissal of the case is subject to the approval of the court. 
Dec 03, 2020 06:00 am ET
Nevro Announces Director Appointment
REDWOOD CITY, Calif., Dec. 3, 2020 /PRNewswire/ -- Nevro Corp. ("Nevro") (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, announced that Susan E. Siegel has been appointed as a member of the Board of Directors (the "Board"), effective December 2, 2020. Ms. Siegel succeeds Wilfred Jaeger, a founding investor in the company with nearly a decade of service to Nevro.
Nov 30, 2020 06:00 am ET
Nevro Appoints Julie D. Dewey as Vice President, Investor Relations and Corporate Communications
REDWOOD CITY, Calif., Nov. 30, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that Julie Dewey has joined the company as vice president, investor relations and corporate communications, effective immediately.  
Nov 24, 2020 06:00 am ET
­Nevro to Participate in Citi Bank Head Shoulders Knees and Toes Conference Call Series on November 30th
REDWOOD CITY, Calif., Nov. 24, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President will participate in Citi Bank's Head Shoulders Knees and Toes Conference Call Series on November 30, 2020 at 2pm ET.
Nov 17, 2020 03:02 pm ET
Nevro Announces Abstract Presentations for PDN and NSRBP Trials Have Been Accepted for the Late Breaking Trials Plenary Session at NANS 2021 Conference
REDWOOD CITY, Calif., Nov. 17, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, announced today that both data abstracts for Painful Diabetic Neuropathy (PDN) and Non-Surgical Refractory Back Pain (NSRBP) were accepted by the North American Neuromodulation Society (NANS 2021) and will be presented at the conference on January 15, 2021. Each presentation will be ten minutes, followed by a two-minute question and answer session. Following both presentations, Nevro Chairman, C
Nov 05, 2020 03:02 pm ET
Nevro Announces Third Quarter 2020 Financial Results
REDWOOD CITY, Calif., Nov. 5, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced its financial results for the third quarter ended September 30, 2020.
Oct 22, 2020 04:05 pm ET
Nevro to Report Third Quarter 2020 Financial Results
REDWOOD CITY, Calif., Oct. 22, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the Company will release its financial results for the third quarter ended September 30, 2020 after the market closes on November 5, 2020.
Aug 07, 2020 07:00 am ET
Nevro to Present at Canaccord Genuity 40th Annual Virtual Growth Conference
REDWOOD CITY, Calif., Aug. 7, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present at the Canaccord Genuity 40th Annual Virtual Growth Conference on August 13, 2020, beginning at approximately 3:30 pm Eastern Time.
Aug 05, 2020 04:10 pm ET
Nevro Announces Second Quarter 2020 Financial Results
REDWOOD CITY, Calif., Aug. 5, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced its financial results for the second quarter ended June 30, 2020.
Jul 20, 2020 07:00 am ET
­Nevro to Report Second Quarter 2020 Financial Results
REDWOOD CITY, Calif., July 20, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the Company will release its financial results for the second quarter ended June 30, 2020 after the market closes on August 5, 2020.
Jun 04, 2020 07:00 am ET
Nevro Appoints Finance Executive Roderick MacLeod as Chief Financial Officer
REDWOOD CITY, Calif., June 4, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the appointment of Roderick ("Rod") MacLeod as Chief Financial Officer, effective June 15, 2020, with global responsibility for Finance, IT and Customer Service.  Mr. MacLeod succeeds Andrew Galligan, who is retiring but will remain with the Company during a transition period.
May 14, 2020 07:00 am ET
Nevro Announces CE Mark Approval of Senza® Omnia™ Spinal Cord Stimulation System to Treat Chronic Pain
REDWOOD CITY, Calif., May 14, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced it has received CE mark approval for the Senza® Omnia™ Spinal Cord Stimulation (SCS) system.
May 05, 2020 04:10 pm ET
Nevro Reports First Quarter 2020 Financial Results
REDWOOD CITY, Calif., May 5, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced its financial results for the first quarter ended March 31, 2020. 
May 04, 2020 07:00 am ET
Nevro To Participate in Upcoming May Conferences
REDWOOD CITY, Calif., May 4, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that Nevro Chairman, CEO and President D. Keith Grossman is scheduled to speak at the following upcoming virtual investor conferences:
Apr 21, 2020 07:00 am ET
Nevro to Report First Quarter 2020 Financial Results
REDWOOD CITY, Calif., April 21, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the Company will release its financial results for the first quarter ended March 31, 2020 after the market closes on May 5, 2020.
Apr 09, 2020 12:42 pm ET
Nevro Announces Federal Circuit Rules in its Favor and Upholds the Validity of Nevro's Patent Claims In Its Litigation Against Boston Scientific
REDWOOD CITY, Calif., April 9, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that in its patent litigation against Boston Scientific the U.S. Court of Appeals for the Federal Circuit issued a ruling in its favor.  The Federal Circuit reversed the district court's indefiniteness rulings, reinstating Nevro's asserted patent claims covering methods and systems for delivering SCS therapy at high frequencies.
Apr 03, 2020 04:44 pm ET
Nevro Announces the Full Exercise of the Underwriter's Option to Purchase Additional Common Stock and the Underwriter's Over-allotment Option to Purchase Additional Convertible Senior Notes
REDWOOD CITY, Calif., April 3, 2020 /PRNewswire/ -- Nevro Corp. ("Nevro") (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the underwriter of each of Nevro's previously announced concurrent public offerings of (a) 1,625,000 shares of its common stock (the "common stock offering") and (b) $165,000,000 aggregate amount of its 2.75% convertible senior notes due 2025 (the "initial notes") (the "notes offering") has fully exercised its option to purchase an additional (a) 243,750 shares of
Apr 02, 2020 08:00 am ET
Nevro Announces Pricing of Public Offerings of Common Stock and Convertible Senior Notes
REDWOOD CITY, Calif., April 2, 2020 /PRNewswire/ -- Nevro Corp. ("Nevro") (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the pricing of concurrent underwritten public offerings of (a) 1,625,000 shares of its common stock at a public offering price of $84.00 per share for gross proceeds, before deducting underwriting discounts and commissions and estimated offering costs, of approximately $136,500,000 (the "common stock offering") and (b) $165,000,000 aggregate amount of its 2.75% converti
Apr 01, 2020 04:40 pm ET
Nevro Announces Proposed Public Offering of Common Stock and Convertible Senior Notes
REDWOOD CITY, Calif., April 1, 2020 /PRNewswire/ -- Nevro Corp. ("Nevro") (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that it has commenced a proposed underwritten public offering of 1,625,000 shares of its common stock (the "common stock offering") and $165,000,000 aggregate principal amount of its convertible senior notes due 2025 (the "notes") (the "notes offering"). All of the shares of common stock to be sold in the common stock offering will be offered by Nevro. In addition, Nevr
Apr 01, 2020 04:07 pm ET
Nevro Provides First Quarter and FY2020 Update
REDWOOD CITY, Calif., April 1, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced preliminary unaudited worldwide revenue for the quarter ended March 31, 2020 and the withdrawal of its full year 2020 financial guidance issued on February 25, 2020.  In addition, the Company provided an update on the actions it is taking in response to the COVID-19 pandemic.
Nov 06, 2019 03:10 pm ET
Nevro Reports Third Quarter 2019 Financial Results
REDWOOD CITY, Calif., Nov. 6, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today reported financial results for the third quarter ended September 30, 2019.
Nov 05, 2019 06:00 am ET
Nevro Announces U.S. Launch of Senza® Omnia™ Spinal Cord Stimulation System to Treat Chronic Pain
REDWOOD CITY, Calif., Nov. 5, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today announced it has received approval from the U.S. Food and Drug Administration (FDA) for the Senza® Omnia™ Spinal Cord Stimulation (SCS) System. The Omnia system is the first and only SCS system designed to deliver Nevro's proprietary HF10® therapy in addition to all other available SCS frequencies.
Oct 10, 2019 07:00 am ET
­Nevro to Report Third Quarter 2019 Financial Results
REDWOOD CITY, Calif., Oct. 10, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the Company will release its financial results for the third quarter ended September 30, 2019 after the market closes on November 6, 2019.
Aug 28, 2019 07:00 am ET
Nevro Announces Completion of Patient Enrollment in Largest Multicenter Randomized Controlled Trial of High Frequency Spinal Cord Stimulation for Painful Diabetic Neuropathy
REDWOOD CITY, Calif., Aug. 28, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain conditions, today announced that it has completed patient enrollment in its prospective, multicenter Randomized Controlled Trial (RCT) for the treatment of chronic pain for patients who suffer from Painful Diabetic Neuropathy (PDN).
Aug 23, 2019 07:00 am ET
Nevro to Present at Morgan Stanley 17th Annual Healthcare Conference
REDWOOD CITY, Calif., Aug. 23, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the Company will be participating in the Morgan Stanley 17th Annual Healthcare Conference in New York City. Nevro Chairman, CEO and President D. Keith Grossman is scheduled to present on Monday, September 9, 2019 at 2:50 pm Eastern Time.
Aug 12, 2019 10:30 am ET
Cellulite Treatment Market Projected to Reach $1,438.5 Billion by 2026
PALM BEACH, Florida, Aug. 12, 2019 /PRNewswire/ -- Cellulite has been the bane of many women (and men too) for years, but the market is expected to rise significantly through 2026, industry reports project. One report said that the global cellulite treatment market size was valued at USD $273.94 million in 2018 and is expected to register a CAGR of 8.2% through 2026. Another report added that the global cellulite treatment market was valued at around US$ 619.2 Mn in 2017 and is anticipated to reach US $1,438.5 Mn by 2026, expanding at a CAGR of 10.1% from 2018 to 2026.The second report opine
Aug 08, 2019 04:10 pm ET
Nevro Reports Second Quarter 2019 Financial Results
REDWOOD CITY, Calif., Aug. 8, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today reported financial results for the second quarter ended June 30, 2019.
Jul 25, 2019 07:00 am ET
Nevro Announces Court Order Granting Preliminary Injunction Against Stimwave Technologies, Inc.
REDWOOD CITY, Calif., July 25, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that U.S. District Judge Colm Connolly, in the District of Delaware, granted Nevro's motion for preliminary injunction, and has issued an order barring Stimwave Technologies, Inc., and all affiliated persons and entities, from infringing patent claims covering frequencies between 3 kHz and 10 kHz by programming Stimwave's SCS systems to deliver its recently introduced high-frequen
Jul 15, 2019 04:30 pm ET
­Nevro to Report Second Quarter 2019 Financial Results
REDWOOD CITY, Calif., July 15, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the Company will release its financial results for the second quarter ended June 30, 2019 after the market closes on August 8, 2019.
May 26, 2019 04:00 pm ET
Nevro to Highlight Substantial Body of Clinical Evidence Supporting Expanded Applications and Unique Capabilities of HF10 Therapy at the 14th International Neuromodulation Society World Congress
SYDNEY, May 26, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced a series of data presentations supporting the use of the Company's HF10™ therapy for patients with chronic pain.  Results will be presented at the International Neuromodulation Society (INS) meeting being held this week in Sydney, Australia.
May 20, 2019 05:00 pm ET
­Nevro Names D. Keith Grossman Chairman of the Board; Michael DeMane as Lead Director
REDWOOD CITY, Calif., May 20, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that its Board of Directors has elected D. Keith Grossman, the Company's President and CEO, to additionally serve as Chairman of the Board.  Mr. Grossman assumes the Chairmanship effective today, following the Company's Annual Meeting of Stockholders.  Michael DeMane, who served as Chairman of the Board since January of 2017, will serve as Lead Director. 
May 09, 2019 04:10 pm ET
Nevro Reports First Quarter 2019 Financial Results
REDWOOD CITY, Calif., May 9, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today reported financial results for the first quarter ended March 31, 2019.
Apr 30, 2019 08:00 pm ET
­Nevro to Present at the Bank of America Merrill Lynch Healthcare Conference 2019
REDWOOD CITY, Calif., April 30, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the Company will be participating in the Bank of America Merrill Lynch Healthcare Conference 2019 in Las Vegas, NV.  President and CEO Keith Grossman is scheduled to present on Tuesday, May 14, 2019 at 3:00 pm Pacific Time.
Apr 23, 2019 07:00 am ET
Nevro to Report First Quarter 2019 Financial Results
REDWOOD CITY, Calif., April 23, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the Company will release its financial results for the first quarter ended March 31, 2019 after market close on May 9, 2019.
Mar 27, 2019 07:20 am ET
Consolidated Research: 2019 Summary Expectations for ADT, HudBay Minerals, Whirlpool, Akebia Therapeutics, Nevro, and MicroStrategy — Fundamental Analysis, Key Performance Indications
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of ADT Inc. (NYSE:ADT), HudBay Minerals Inc (NYSE:HBM), Whirlpool...
Mar 20, 2019 09:31 am ET
Thinking about buying stock in Aurora Cannabis Inc., China Bat Group Inc., Nevro Corp., Shineco Inc., or Vaxart Inc.?
NEW YORK, March 20, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, GLG, NVRO, TYHT, and VXRT.
Mar 19, 2019 04:36 pm ET
Nevro Announces New CEO, Board Appointments and Agreement with Broadfin Capital
REDWOOD CITY, Calif., March 19, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO) ("Nevro"), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman has been appointed President and Chief Executive Officer of Nevro and a member of the Board of Directors (the "Board"), effective today. Mr. Grossman succeeds Rami Elghandour, who has stepped down as President, CEO and a director of the Company. Nevro also appointed two new independent directors, Elizabeth ("Bess") Weatherman and Kevin O'Boyle, ef
Feb 21, 2019 03:10 pm ET
Nevro Reports Fourth Quarter and Full Year 2018 Financial Results
REDWOOD CITY, Calif., Feb. 21, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today reported financial results for the fourth quarter and full year ended December 31, 2018.
Feb 15, 2019 07:00 am ET
Nevro Files Lawsuit for Patent Infringement Against Stimwave in the U.S.
REDWOOD CITY, Calif., Feb. 15, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it has filed a lawsuit for patent infringement against Stimwave Technologies, Inc.  The lawsuit, filed in the United States District Court for the District of Delaware on February 14, 2019, asserts that Stimwave is infringing Nevro's patents covering inventions relating to Nevro's groundbreaking Senza® system and HF10® therapy.  The lawsuit seeks preliminary and permanent inj
Feb 07, 2019 04:45 pm ET
Nevro to Report Fourth Quarter and Full Year 2018 Financial Results
REDWOOD CITY, Calif., Feb. 7, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the company will release its financial results for the fourth quarter and full year 2018, ended December 31, 2018, after market close on February 21, 2019.
Feb 01, 2019 08:10 am ET
Market Trends Toward New Normal in CoreLogic, Nasdaq, Nevro, Blue Apron, Unisys, and Trevena — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CoreLogic, Inc. (NYSE:CLGX), Nasdaq, Inc. (NASDAQ:NDAQ), Nevro Corp....
Jan 10, 2019 07:19 pm ET
Glancy Prongay & Murray LLP Commences Investigation On Behalf Of Nevro Corp. Investors (NVRO)
Glancy Prongay & Murray LLP (“GPM”) announces that it is investigating potential claims on behalf of investors of Nevro Corp. (NYSE: NVRO) (“Nevro” or “the Company”) and whether the Company’s officers and directors complied with their legal...
Jan 07, 2019 08:00 am ET
Nevro Announces Preliminary Unaudited Fourth Quarter and Full Year 2018 Revenue
REDWOOD CITY, Calif., Jan. 7, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced its preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2018.
Dec 20, 2018 03:10 pm ET
Nevro to Present at the 37th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Dec. 20, 2018 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the company will be participating in the upcoming 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
Nov 12, 2018 08:20 am ET
Research Report Identifies DXP Enterprises, Diebold Nixdorf, Fitbit, Nevro, Plains All American Pipeline, and Cara Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movemen
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of DXP Enterprises, Inc. (NASDAQ:DXPE), Diebold Nixdorf, Incorporated...
Nov 08, 2018 06:22 pm ET
Robbins Arroyo LLP: Officers and Directors of Nevro Corp. (NVRO) Breached Their Fiduciary Duties According to Shareholder Lawsuit
Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Nevro Corp. (NYSE: NVRO) have filed a shareholder lawsuit against the company's officers and directors for breaches of their fiduciary duties from January 8, 2016 through the present. Nevro is a medical device company that provides pr
Nov 07, 2018 09:26 pm ET
Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Nevro Corporation (NVRO) and Encourages NVRO Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Nevro Corporation (NYSE: NVRO). On August 23, 2018, a complaint was filed alleging that between January 8, 2018 and July 12, 2018, defendants...
Nov 05, 2018 03:10 pm ET
Nevro Reports Third Quarter 2018 Financial Results
REDWOOD CITY, Calif., Nov. 5, 2018 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today reported financial results for the three and nine months ended September 30, 2018.
Oct 22, 2018 04:42 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nevro Corporation to Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Nevro Corporation (“Nevro” or the “Company”) (NYSE:NVRO) of the October 22, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Oct 22, 2018 10:00 am ET
DEADLINE ALERT- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nevro Corp. (NVRO) and Lead Plaintiff Deadline – October 22, 2018
Attorney Advertising-- Bronstein, Gewirtz Grossman, LLC reminds investors that a class action lawsuit has been filed against Nevro Corp. (“Nevro” or the “Company”) (NYSE: NVRO) and certain of its officers, on behalf of shareholders who purchased...
Oct 22, 2018 08:45 am ET
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nevro Corp. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nevro Corp. (“Nevro” or “the Company”) (NASDAQ:
Oct 21, 2018 10:50 pm ET
NEVRO 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit against Nevro Corp. - NVRO
ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until October 22, 2018 to file lead plaintiff applications in a securities class action lawsuit against Nevro Corp. (NYSE: NVRO). Investor losses must relate to purchases of the Company’s shares between January 8, 2018 and July 12, 2018. This action is pending in the United States District Court for the Northern District of California.
Oct 21, 2018 11:00 am ET
SHAREHOLDER ALERT: AMPE NVRO PZZA OPK QRTEA MCHP COCP TGTX CPB TRVN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Oct 19, 2018 10:50 pm ET
NEVRO 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until October 22, 2018 to file lead plaintiff applications in a securities class action lawsuit against Nevro Corp. (NYSE: NVRO). Investor losses must relate to purchases of the Company’s shares between January 8, 2018 and July 12, 2018. This action is pending in the United States District Court for the Northern District of California.
Oct 19, 2018 07:23 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nevro Corporation - NVRO
Pomerantz LLP is investigating claims on behalf of investors of Nevro Corporation (“Nevro” or the “Company”) (NYSE: NVRO).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Oct 19, 2018 04:59 pm ET
Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Nevro Corp.
National class action law firm Glancy Prongay Murray LLP (“GPM”) reminds investors of the October 22, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Nevro Corp. (“Nevro” or the...
Oct 19, 2018 04:55 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nevro Corporation To Contact The Firm
NEW YORK, Oct. 19, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Nevro Corporation ("Nevro" or the "Company") (NYSE:NVRO) of the October 22, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Oct 19, 2018 12:01 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PDD, AMPE, NVRO, PZZA and TRCO
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Oct 18, 2018 11:31 am ET
CLASS ACTION UPDATE for AMPE, NVRO and LOGM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Oct 18, 2018 07:45 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Chicago Rivet & Machine, Capstone Turbine, Ennis, Fiesta Restaurant Group, Diebold Nixdorf, and Nevro — New Research Emphasizes Econ
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Chicago Rivet Machine Co. (NYSE:CVR), Capstone Turbine Corporation...
Oct 17, 2018 03:07 pm ET
SHAREHOLDER ALERT: PDD AMPE NVRO LCI CBS PZZA OPK QRTEA PVG COCP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Oct 17, 2018 12:00 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AMPE, NVRO, LCI, LOGM and HTHT
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Oct 16, 2018 07:52 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against LogMeIn, Pinduoduo, Nevro, and CV Sciences and Encourages Investors to Contact the Firm
Bragar Eagel Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of LogMeIn, Inc., Pinduoduo Inc., Nevro Corp., and CV Sciences, Inc.  Stockholders have until the deadlines listed below to...
Oct 16, 2018 11:45 am ET
CLASS ACTION UPDATE for AMPE, NVRO and LCI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Oct 15, 2018 02:28 pm ET
FINAL DEADLINE ALERT:  Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Nevro Corp. (NYSE
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of Nevro...
Oct 15, 2018 10:00 am ET
DEADLINE ALERT- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nevro Corp. (NVRO) and Lead Plaintiff Deadline – October 22, 2018
Attorney Advertising -- Bronstein, Gewirtz Grossman, LLC reminds investors that a class action lawsuit has been filed against Nevro Corp. (“Nevro” or the “Company”) (NYSE: NVRO) and certain of its officers, on behalf of shareholders who purchased...
Oct 14, 2018 10:09 am ET
SHAREHOLDER ALERT: NVRO LCI CBS PZZA LOGM SKX OPK PM: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Oct 12, 2018 10:50 pm ET
NEVRO SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Nevro Corp. - NVRO
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 22, 2018 to file lead plaintiff applications in a securities class action lawsuit against Nevro Corp. (NYSE: NVRO), if they purchased the Company’s...
Oct 12, 2018 07:16 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nevro Corporation - NVRO
Pomerantz LLP is investigating claims on behalf of investors of  Nevro Corporation (“Nevro” or the “Company”) (NYSE: NVRO).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Oct 12, 2018 01:00 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NVRO, LOGM, USAT, ABBV and ALNY
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Oct 11, 2018 04:05 pm ET
Nevro to Report Operating Results for the Third Quarter 2018
REDWOOD CITY, Calif., Oct. 11, 2018 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical technology company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it will release financial results for the third quarter of 2018 after market close on Monday, November 5, 2018. Company management will host a conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Monday, November 5, 2018.
Oct 11, 2018 02:22 pm ET
CLASS ACTION UPDATE for PDD and NVRO: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Oct 10, 2018 05:16 pm ET
The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nevro Corp. (NVRO)
Law Offices of Howard G. Smith reminds investors of the October 22, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Nevro Corp. (“Nevro” or the “Company”) (NYSE: NVRO) securities between January 8, 2018 and July 12, 2018, inclusive (the “Clas
Oct 10, 2018 02:59 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AMPE, NVRO and MGTI
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Oct 10, 2018 10:00 am ET
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nevro Corp. (NVRO) and Lead Plaintiff Deadline – October 22, 2018
Attorney Advertising -- Bronstein, Gewirtz Grossman, LLC reminds investors that a class action lawsuit has been filed against Nevro Corp. (“Nevro” or the “Company”) (NYSE: NVRO) and certain of its officers, on behalf of shareholders who purchased...
Oct 09, 2018 03:11 pm ET
NEVRO INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Nevro Corporation To Contact The Firm
Faruqi Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nevro Corporation (“Nevro” or the “Company”) (NYSE:NVRO). If you invested in Nevro stock or options and would like to discuss your legal...
Oct 09, 2018 12:00 pm ET
SHAREHOLDER ALERT: TSLA PDD AMPE NVRO ORCL NLSN ZN SBGI OPK COCP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Oct 08, 2018 06:48 pm ET
Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Nevro Corp.
National class action law firm Glancy Prongay & Murray LLP (“GPM”) reminds investors of the October 22, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Nevro Corp. (“Nevro” or the “Company”) (NYSE:
Oct 07, 2018 10:15 am ET
CLASS ACTION UPDATE for AMPE, NVRO and CBS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Oct 05, 2018 10:50 pm ET
NEVRO SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Nevr
Kahn Swick Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 22, 2018 to file lead plaintiff applications in a securities class action lawsuit against...
Oct 05, 2018 05:24 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Nevro Corporation - NVRO
Pomerantz LLP is investigating claims on behalf of investors of  Nevro Corporation (“Nevro” or the “Company”) (NYSE: NVRO).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Oct 05, 2018 03:21 pm ET
Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Nevro Corporation Investors
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased Nevro Corporation (“Nevro” or the “Company”) (NYSE: NVRO) securities between January 8, 2018 and July 12, 2018, inclusive (the “Class Period”). Nevro investors have until October 22,
Oct 05, 2018 11:50 am ET
SHAREHOLDER ALERT: PDD AMPE NVRO LCI CBS PZZA LOGM SKX PM QRTEA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Oct 05, 2018 10:00 am ET
SHAREHOLDER ALERT- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nevro Corp. (NVRO) and Lead Plaintiff Deadline – October 22, 2018
Attorney Advertising -- Bronstein, Gewirtz Grossman, LLC reminds investors that a class action lawsuit has been filed against Nevro Corp. (“Nevro” or the “Company”) (NYSE: NVRO) and certain of its officers, on behalf of shareholders who purchased...
Oct 03, 2018 06:56 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Nevro, CV Sciences, and Lannett and Encourages Investors to Contact the Firm
Bragar Eagel Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Nevro Corp., CV Sciences, Inc., and Lannett Company, Inc.  Stockholders have until the deadlines listed below to petition the...
Sep 30, 2018 10:03 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TSLA, AMPE, NVRO, CBS and SKX
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Sep 28, 2018 10:50 pm ET
NEVRO HOLDINGS SHAREHOLDER ALERT: ClaimsFiler Reminds Investors with Losses in Excess of $100,000 Of Lead Plaintiff Deadline in Class Action Lawsuit Against Nevro Corp. - NVRO
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 22, 2018 to file lead plaintiff applications in a securities class action lawsuit against Nevro Corp. (NYSE: NVRO), if they purchased the Company’s shares between January 8, 2018 and July 12, 2018, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Sep 28, 2018 07:27 pm ET
NEVRO INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Nevro Corporation To Contact The Firm
NEW YORK, Sept. 28, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nevro Corporation ("Nevro" or the "Company") (NYSE:NVRO).
Sep 28, 2018 05:47 pm ET
Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Nevro Corp. Investors (NVRO)
Glancy Prongay & Murray LLP (“GPM”) announces that a class action lawsuit has been filed on behalf of investors that purchased or otherwise acquired securities of Nevro Corp. (“Nevro” or the “Company”) (NYSE: 
Sep 28, 2018 03:15 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nevro Corporation - NVRO
Pomerantz LLP is investigating claims on behalf of investors of  Nevro Corporation (“Nevro” or the “Company”) (NYSE: NVRO).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Sep 28, 2018 01:39 pm ET
SHAREHOLDER ALERT: TSLA PDD NVRO ORCL LOGM NLSN ZN SBGI HMNY GDS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Sep 28, 2018 10:00 am ET
SHAREHOLDER ALERT- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nevro Corp. (NVRO) and Lead Plaintiff Deadline – October 22, 2018
Attorney Advertising--(PR Newswire)--Bronstein, Gewirtz Grossman, LLC reminds investors that a class action lawsuit has been filed against Nevro Corp. (“Nevro” or the “Company”) (NYSE: NVRO) and certain of its officers, on behalf of shareholders...
Sep 27, 2018 03:42 pm ET
CLASS ACTION UPDATE for NVRO and PZZA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Sep 27, 2018 12:55 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NVRO, LCI, PZZA, PM, and PVG
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Sep 26, 2018 03:28 pm ET
SHAREHOLDER ALERT: NVRO PZZA NLSN ZN HMNY GDS PVG OPK USAT MCHP COCP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Sep 23, 2018 09:15 am ET
CLASS ACTION UPDATE for NVRO, PZZA and PVG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Sep 21, 2018 10:50 pm ET
NEVRO HOLDINGS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Nevro Corp. - NVRO
NEW ORLEANS, Sept. 21, 2018 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 22, 2018 to file lead plaintiff applications in a securities class action lawsuit against Nevro Corp. (NYSE: NVRO), if they purchased the Company's shares between January 8, 2018 and July 12, 2018, inclusive (the "Class Period").  This action is pending in the United States District Court for the Northern District of California.
Sep 20, 2018 05:31 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AMPE, NVRO, LCI, CBS, PZZA, SKX, CRON, PM and QRTEA
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Sep 20, 2018 10:00 am ET
SHAREHOLDER ALERT- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nevro Corp. (NVRO) and Lead Plaintiff Deadline – October 22, 2018
Attorney Advertising -- Bronstein, Gewirtz Grossman, LLC reminds investors that a class action lawsuit has been filed against Nevro Corp. (“Nevro” or the “Company”) (NYSE: NVRO) and certain of its officers, on behalf of shareholders who purchased...
Sep 18, 2018 08:03 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Oracle, Pinduoduo, and Nevro and Encourages Investors to Contact the Firm
Bragar Eagel Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Oracle Corporation, Pinduoduo Inc., and Nevro Corp.  Stockholders have until the deadlines listed below to petition the court...
Sep 18, 2018 12:00 pm ET
SHAREHOLDER ALERT: AMPE NVRO PZZA LOGM NLSN ZN GDS SKX PM QRTEA CRON: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Sep 17, 2018 02:00 pm ET
CLASS ACTION UPDATE for AMPE, NVRO, PZZA and LOGM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Sep 16, 2018 01:15 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AMPE, NVRO, PZZA, PM, and QRTEA
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Sep 14, 2018 10:50 pm ET
NEVRO SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Nevr
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 22, 2018 to file lead plaintiff applications in a securities class action lawsuit against Nevro Corp. (NYSE: NVRO), if they purchased the Company’s shares between January 8, 2018 and July 12, 2018, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Sep 14, 2018 07:59 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nevro Corporation - NVRO
Pomerantz LLP is investigating claims on behalf of investors of  Nevro Corporation (“Nevro” or the “Company”) (NYSE: NVRO).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.